Vaxcyte Completes Enrollment in Phase 3 Trials for VAX-31 Pneumococcal Vaccine

Vaxcyte has completed enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a pneumococcal conjugate vaccine candidate. The OPUS-1 trial will establish a new standard for adult pneumococcal conjugate vaccines, while the OPUS-2 trial evaluates concomitant administration of VAX-31 and a seasonal influenza vaccine. Topline data from OPUS-1 is expected in Q4 2026, and results from OPUS-2 and OPUS-3 trials are expected in H1 2027. The Phase 3 program aims to generate a broad dataset to support a planned BLA submission.